RCDOP方案治疗87例弥漫大B细胞淋巴瘤患者疗效分析
Open Access
- 14 June 2018
- journal article
- Vol. 39 (6), 485-490
Abstract
评估RCDOP(利妥昔单抗、环磷酰胺、脂质体多柔比星、长春新碱、泼尼松)方案在弥漫大B细胞淋巴瘤(DLBCL)患者中的疗效。 回顾性分析2012年10月至2017年10月应用RCDOP方案治疗的87例初治DLBCL患者资料,结合临床特征进行疗效和生存分析。 ①87例患者中,男40例,女47例,中位年龄60(14~84)岁。应用RCDOP方案治疗后,获得完全缓解(CR)和部分缓解(PR)者共计81例(93.10%)。②根据IPI评分不同危险度分层(低、中、高危)、结外累及部位(0~1个/≥2个)、肿块大小(60岁)、LDH(正常/升高)、Ann Arbor分期(Ⅰ~Ⅱ期/Ⅲ~Ⅳ期)、Ki-67阳性率(>80%/≤80%)对患者进行分组,比较组间无进展生存(PFS)和总生存(OS)的差异。结果显示,RCDOP方案治疗后,中位随访时间为9个月,IPI评分低、中、高危三组患者的1年PFS率(P=0.084)和OS率(P=0.515)差异无统计学意义,其余组间比较患者的1年PFS率和OS率差异也均无统计学意义(P值均>0.05)。 RCDOP方案可以改善IPI评分中高危、结外多部位累及、巨大肿块、年龄>60岁、高LDH、Ann Arbor分期Ⅲ~Ⅳ期和Ki-67阳性率>80%患者的早期疗效。Keywords
This publication has 17 references indexed in Scilit:
- [Consensus on the management of lymphoma with HBV infection].Chinese Journal of Hematology, 2013
- Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphomaLeukemia & Lymphoma, 2011
- Non-Hodgkin’s lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcomeAnnals of Oncology, 2007
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphomaLeukemia & Lymphoma, 2006
- Pegylated Liposomal Doxorubicin and Cyclophosphamide as First-Line Therapy for Patients with Metastatic or Recurrent Breast CancerClinical Breast Cancer, 2005
- Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review).Oncology Reports, 2004
- The Limits of Limited Stage LymphomaJournal of Clinical Oncology, 2004
- A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.1997
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaThe New England Journal of Medicine, 1993